Silence Therapeutics Upsizes Public Offering by $40M to $190M, Capitalizing on Positive Phase 2 Data
SLN has more than doubled off its 52-week low of $4.19 on elevated volume (4.4× avg).
Summary
Silence Therapeutics upsized its public offering by $40 million to $190 million, capitalizing on strong demand following positive Phase 2 data for divesiran. The additional capital extends the cash runway but increases dilution.
Updates
· SEC 424B5 — The 424B5 prospectus supplement sets the offering at 12,962,963 ADSs for $175,000,000.50 gross proceeds, with net proceeds of approximately $164.0 million ($188.7 million if the underwriters' option is fully exercised).
· BusinessWire — Silence Therapeutics priced the upsized offering at $13.50 per ADS, expecting $175 million in gross proceeds, a 9.3% discount to the last close. Underwriters have a 30-day option for 1.9 million additional ADSs, with closing expected August 13.
Key Events · Financing and Capital Events · SLN
-
Offering Upsized by $40M
Silence Therapeutics registered an additional $40 million of ordinary shares, increasing the total offering size from $150 million to $190 million. The upsizing follows strong demand after positive Phase 2 divesiran data.
-
Financial Impact
The additional $40 million brings total potential proceeds to $190 million, significantly extending the company's cash runway beyond 2028. Dilution increases proportionally, with the offering now representing a larger portion of the company's market cap.
-
Timing and Context
The upsizing comes one day after the initial $150 million offering was launched on August 10, 2026, which itself was announced hours after the Phase 2 SANRECO trial results showed 88% of treated patients achieved the primary endpoint.
-
Prior-Disclosure Context
This S-3MEF relates to the Prior Registration Statement (File No. 333-295992) filed May 18, 2026, which had $200 million of unsold securities. The additional $40 million represents no more than 20% of that unsold amount, as permitted by Rule 462(b).
Analysis · SLN · Life Sciences
Just one day after launching a $150 million underwritten public offering, Silence Therapeutics is increasing its size to $190 million. The move comes on the heels of blockbuster Phase 2 data for divesiran in polycythemia vera, where 88% of treated patients achieved the primary endpoint. The upsizing signals robust institutional demand and enables the company to raise more capital at a favorable price, further extending its cash runway. However, it also amplifies dilution for existing shareholders. The additional $40 million represents a 27% increase over the original $150 million offering, a significant boost that underscores confidence in the company's clinical momentum.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLN was trading at $14.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $728.8M. The 52-week trading range was $4.19 to $17.58. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.